Skip to main content
Smart Investors Daily
FN

NYSE · FNA

Paragon 28, Inc.

Healthcare · Medical - Devices

$13.09

Up+$0.00 (+0.00%)

Updated Oct 6, 2026, 11:22 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.1B
P/E ratio
-29.28
Dividend yield
0.00%
52-week range
$4.65 – $13.13
Volume
19.38M
Avg. volume
2.57M

Price performance · FNA

FNA price history

1M range · 0 trading sessions · Daily adjusted prices

FNA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest FNA news

The latest Smart Investors Daily articles mentioning FNA.

FNA research

Overview

Company profile and research snapshot.

Company profile

Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$12.00
Implied upside
—
Analysts
10
FNA recent ratings
DateFirmRatingTarget
Jan 30, 2025Stephens & Co.Equal-Weight—
Jan 29, 2025William BlairMarket Perform—
Jan 29, 2025NeedhamHold—
Jan 29, 2025Canaccord GenuityHold—
Jan 13, 2025NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Nov 28, 2024

FNA DEADLINE ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Paragon 28, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 29 Deadline in Securities Class Action First Filed by the Firm – FNA

Rosen Law Firm is encouraging investors who purchased Paragon 28, Inc. common stock or options between May 5, 2023 and September 20, 2024 to join a securities class action lawsuit before the November 29, 2024 deadline. The lawsuit alleges that Paragon 28 made materially false and misleading statements about its financial performance.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.